European Biotechs Unveil Next-Gen CGT Manufacturing to Cut CAR-T Costs Above €60,000 Per Patient

July 5, 2026

PharmTech Global

Overview

European biopharmaceutical companies are spearheading the development of advanced manufacturing technologies to address the high costs and logistical hurdles of Cell and Gene Therapies (CGT). Innovations include automated closed-loop platforms, scalable lentiviral vector CDMO capacities, enzymatic synthetic DNA production, and bioreactor-based stem cell expansion. These technologies are critical for reducing the current CAR-T therapy cost, which often exceeds €60,000 per patient, enhancing accessibility and market penetration.

In Depth

Key Findings

European biotechnology firms are leading breakthroughs in next-generation manufacturing technologies for Cell and Gene Therapies (CGTs), specifically targeting the substantial reduction of current CAR-T therapy costs, which can exceed €60,000 per patient. These advancements aim to overcome critical manufacturing and supply chain challenges, making these transformative treatments more accessible globally.

Technical / Clinical Details

Key technological advancements being championed include:

Automated Closed-Loop Platforms: These systems minimize human intervention, drastically reducing contamination risks and ensuring high consistency in CGT product manufacturing.
Scalable Lentiviral Vector CDMO Capabilities: Companies like Oxford Biomedica are expanding their capacities to produce lentiviral vectors at scale, which are crucial for gene delivery in therapies like CAR-T.
Enzymatic Synthetic DNA: Touchlight Genetics is at the forefront of enzymatic DNA synthesis, offering a faster and more flexible alternative to traditional plasmid DNA production, essential for rapid therapy development.
Bioreactor-Based Stem Cell Expansion: This enables efficient, large-scale cultivation of stem cells, laying the groundwork for developing allogeneic, ‘off-the-shelf’ cell therapies.

These integrated approaches are designed to streamline the complex manufacturing processes inherent in personalized medicine, improving both cost-effectiveness and product quality and safety profiles.

Background & Context

Despite their groundbreaking efficacy, CGTs have been hampered by prohibitive costs and intricate manufacturing logistics. Autologous therapies, requiring patient-specific customization, contribute significantly to these high expenditures and logistical complexities. The European Union is actively investing in R&D and regulatory frameworks to integrate CGTs into a more sustainable healthcare model, recognizing the urgent need for scalable and affordable production methods.

Strategic Significance & Outlook

The widespread adoption of these next-generation manufacturing technologies is expected to dramatically improve CGT production efficiency and lower costs. This will broaden patient access to life-saving treatments and accelerate the growth of the overall CGT market. Furthermore, the standardization and automation of manufacturing processes are anticipated to stabilize global supply chains, paving the way for CGTs to become a more routine and widely available therapeutic option.

Source: https://www.pharmtech.com/view/european-biotechs-developing-next-generation-cell-and-gene-therapy-manufacturing-technologies

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.